Talphera Inc
NASDAQ:TLPH

Watchlist Manager
Talphera Inc Logo
Talphera Inc
NASDAQ:TLPH
Watchlist
Price: 1.23 USD 6.03% Market Closed
Market Cap: 57.3m USD

Talphera Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Talphera Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Talphera Inc
NASDAQ:TLPH
Revenue
$28k
CAGR 3-Years
N/A
CAGR 5-Years
-65%
CAGR 10-Years
-48%
Johnson & Johnson
NYSE:JNJ
Revenue
$92.1B
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$48B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$62.8B
CAGR 3-Years
-14%
CAGR 5-Years
9%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Revenue
$64.2B
CAGR 3-Years
3%
CAGR 5-Years
13%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Revenue
$59.4B
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
12%
No Stocks Found

Talphera Inc
Glance View

Market Cap
56.1m USD
Industry
Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 19 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The firm's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The firm is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.

TLPH Intrinsic Value
Not Available

See Also

What is Talphera Inc's Revenue?
Revenue
28k USD

Based on the financial report for Sep 30, 2025, Talphera Inc's Revenue amounts to 28k USD.

What is Talphera Inc's Revenue growth rate?
Revenue CAGR 10Y
-48%

Over the last year, the Revenue growth was -90%.

Back to Top